Discover
MRKR
Marker Therapeutics, Inc.
1.45
2 x 1.07
2 x 1.88
bid
ask
-
0.02
1.36%
2 @ 04:00 PM
1.45 +0.00 (0.00%)
| Ytd | -2.68% | |
| 1y | -3.97% |
1.45
day range
1.50
0.81
52 week range
4.07
| Open | 1.46 | Prev Close | 1.47 | Low | 1.45 | High | 1.50 | Mkt Cap | 24.18M |
| Vol | 46.55K | Avg Vol | 87.21K | EPS | -0.55 | P/E | N/A | Forward P/E | -2.34 |
| Beta | 1.49 | Short Ratio | 1.55 | Inst. Own | 22.44% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 1.43 | 200-d Avg | 1.36 | 1yr Est | 19.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | 0 | -0.26 | N/A | N/A |
| 2024-08-14 | 2024-06 | 0 | -0.25 | N/A | N/A |
| 2024-05-15 | 2024-03 | 0 | -0.27 | N/A | N/A |
| 2024-03-27 | 2023-12 | 0 | N/A | N/A | N/A |
| 2023-11-09 | 2023-09 | 0 | -0.34 | N/A | N/A |
| 2023-08-14 | 2023-06 | 0 | -0.47 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-04-30 | Ladenburg Thalmann | Upgrade | Buy |
Profile
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | NEA Management Company, LLC | 1.07M | 3.66M | 12.01% |
| 2024-09-29 | Aisling Capital Management LP | 314.29K | 1.07M | 3.52% |
| 2024-09-29 | Vanguard Group Inc | 243.12K | 831.48K | 2.72% |
| 2024-09-29 | AR Asset Management, Inc. | 73.70K | 252.05K | 0.83% |
| 2024-09-29 | Geode Capital Management, LLC | 71.56K | 244.74K | 0.80% |
| 2024-09-29 | Renaissance Technologies, LLC | 39.75K | 135.95K | 0.45% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 153.47K | 524.88K | 1.72% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 87.14K | 298.01K | 0.98% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 39.95K | 136.62K | 0.45% |
| 2024-10-30 | iShares Micro Cap ETF | 16.58K | 56.70K | 0.19% |
| 2024-07-30 | DFA U.S. Small Cap Series | 15.90K | 54.38K | 0.18% |
| 2024-10-30 | Fidelity Total Market Index Fund | 12.81K | 43.81K | 0.14% |
Split
| Split | Date |
|---|---|
| 1 : 10 | 2023-01-27 |
| 1 : 12 | 2016-09-16 |
| 1 : 100 | 2014-02-25 |
| 0.1 : 1 | 2009-07-27 |
| 0.4 : 1 | 2007-06-28 |